A
Andrew J. Pierce
High Impact
Senior Vice President
faculty
34 h-index
171 pubs
7,569 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Andrew J. Pierce's research focuses on cancer treatment and pharmacology, particularly investigating novel therapeutic agents and their mechanisms of action. He has been involved in clinical trials for agents like ceralasertib, an ATR kinase inhibitor, exploring its efficacy in combination with chemotherapy regimens such as carboplatin and paclitaxel for advanced and refractory solid tumors. His work also examines the role of DNA damage response pathways in predicting treatment outcomes, with a specific interest in biomarkers like Schlafen11 (SLFN11).
Further research by Pierce explores the intersection of immunotherapy and DNA repair mechanisms. This includes investigating how ATR inhibitors can enhance cancer immunotherapy by modulating the tumor microenvironment. Additionally, his publications address the development and application of bispecific antibodies, such as those targeting PD-1 and LAG-3 on T cells to promote anti-tumor activity, and dual-targeting Humabody therapeutics for specific tumor types like PSMA-positive cancers. His work also involves the development and application of mass spectrometry for quantifying pharmacodynamic biomarkers related to kinase inhibition, such as ATM kinase.
Metrics
- h-index: 34
- Publications: 171
- Citations: 7,569
Selected Publications
-
High-Throughput HPLC Method for the Measurement of Octanol–Water Partition Coefficients without an Organic Modifier (2025)
-
Ritualistic Male–Male Combat of the Northern King Cobra (<scp><i>Ophiophagus hannah</i></scp>) in Thailand (2025)
-
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors (2025)
-
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets (2024)
-
Nest site vegetation structure influences nest predators and nesting success of understory birds in a dry evergreen forest in northeastern Thailand (2024)
-
Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum (2024)
-
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors (2024)
-
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment (2024)
-
Non-breeding season records of warblers in the Phylloscopus reguloides lineage from Thailand and Myanmar (2023)
-
Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023)
-
Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023)
-
Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023)
-
Data from Improved Therapeutic Window in <i>BRCA</i>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition (2023)
-
Data from Improved Therapeutic Window in <i>BRCA</i>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition (2023)
-
Data from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein (2023)
Collaboration Network
Top Collaborators
Qun Du
13 shared publications
- Supplementary Figures 1-14; Supplementary Tables 1-3 from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- supplementary figure legends from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 13 shared publications
Melissa Damschroder
13 shared publications
- Supplementary Figures 1-14; Supplementary Tables 1-3 from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- supplementary figure legends from A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 13 shared publications
Kathy Mulgrew
AstraZeneca (Netherlands) (NL)
12 shared publications
- The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 12 shared publications
Emma Dean
11 shared publications
- Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
- Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
- Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
- Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts
- PLANETTE: A modular phase IIa multicenter open-label study evaluating the ATR inhibitor ceralasertib (AZD6738) in ATM mutant advanced solid tumors.
Showing 5 of 11 shared publications
Michael D. Oberst
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Catherine Augé
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Chad D. Morris
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Stacy Kentner
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Kelly McGlinchey
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
James Hair
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Shino Hanabuchi
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Hui Feng
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Steven Eck
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Nicholas Buss
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Lolke de Haan
11 shared publications
- Figures S8-S10 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S7 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Methods from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
- Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Showing 5 of 11 shared publications
Similar Researchers
Based on overlapping research topics
Marlee Martin
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Pharmacological Effects and Toxicity Studies
Darin Jones
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Pharmacological Effects and Toxicity Studies
Han M
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Pharmacological Effects and Toxicity Studies
Peter A. Crooks
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Pharmacological Effects and Toxicity Studies
Mary Price
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Monoclonal and Polyclonal Antibodies Research
Pharmacological Effects and Toxicity Studies
Darin E. Jones
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
DNA Repair Mechanisms
Pharmacological Effects and Toxicity Studies